J. Załuski

7.4k total citations · 1 hit paper
23 papers, 4.5k citations indexed

About

J. Załuski is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, J. Załuski has authored 23 papers receiving a total of 4.5k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 11 papers in Pulmonary and Respiratory Medicine and 3 papers in Surgery. Recurrent topics in J. Załuski's work include Colorectal Cancer Treatments and Studies (10 papers), Cancer Treatment and Pharmacology (9 papers) and Gastric Cancer Management and Outcomes (6 papers). J. Załuski is often cited by papers focused on Colorectal Cancer Treatments and Studies (10 papers), Cancer Treatment and Pharmacology (9 papers) and Gastric Cancer Management and Outcomes (6 papers). J. Załuski collaborates with scholars based in Poland, France and Germany. J. Załuski's co-authors include Eric Van Cutsem, Gunnar Folprecht, Christopher Stroh, Tamás Pintér, Geert D’Haens, Johannes Nippgen, Robert Lim, Philippe Rougier, Anatoly Makhson and Jae Kyung Roh and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Annals of Oncology.

In The Last Decade

J. Załuski

23 papers receiving 4.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer

2009 2.9k citations Eric Van Cutsem, Claus-Henning Köhne et al. New England Journal of Medicine profile →

Peers

Countries citing papers authored by J. Załuski

Since Specialization

Citations

This map shows the geographic impact of J. Załuski's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. Załuski with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. Załuski more than expected).

Fields of papers citing papers by J. Załuski

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J. Załuski. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. Załuski. The network helps show where J. Załuski may publish in the future.

Co-authorship network of co-authors of J. Załuski

This figure shows the co-authorship network connecting the top 25 collaborators of J. Załuski. A scholar is included among the top collaborators of J. Załuski based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J. Załuski. J. Załuski is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer breakdown → 2009 ·New England Journal of Medicine ·Eric Van Cutsem, Claus-Henning Köhne, Erika Hitre, J. Załuski, (unknown), Anatoly Makhson, Geert D’Haens, Tamás Pintér, Robert Lim, G. Bodoky, Jae Kyung Roh, Gunnar Folprecht, Paul Ruff, Christopher Stroh, Sabine Tejpar, Michael Schlichting, Johannes Nippgen, Philippe Rougier	2902
2	Quality of life of palliative chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction treated with irinotecan combined with 5-fluorouracil and folinic acid: results of a randomised phase III trial 2009 ·Quality of Life Research ·Desmond Curran, Carmelo Pozzo, J. Załuski, Magdolna Dank, Carlo Barone, Vahur Valvere, Şuayib Yalçın, Christian Peschel, M. Wenczl, Erdem Göker, R. Bugat	30
3	The crystal study: Assessment of the predictive value of KRAS status on clinical outcome in patients with mcrc receiving first-line treatment with cetuximab or cetuximab plus folfiri 2008 ·Annals of Oncology ·Eric Van Cutsem, István Láng, G D’Haens, (unknown), J. Załuski, (unknown), Gunnar Folprecht, Sabine Tejpar, Yaroslav Shparyk, M. Schlichting, O. Kisker, Christopher Stroh, P Rougier	11
4	Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction 2008 ·Annals of Oncology ·Magdolna Dank, J. Załuski, Carlo Barone, Vahur Valvere, Sıddika Songül Yalçın, Christian Peschel, M. Wenczl, Erdem Göker, Laura A. Cisar, (unknown), R. Bugat	250
5	Two different first-line 5-fluorouracil regimens with or without oxaliplatin in patients with metastatic colorectal cancer 2008 ·Annals of Oncology ·David Cunningham, Bhawna Sirohi, A Płużańska, B. Utracka-Hutka, J. Załuski, Rob Glynne‐Jones, P. Koralewski, John Bridgewater, Paul N. Mainwaring, Harpreet Wasan, (unknown), Cezary Szczylik, P. Clingan, (unknown), Isabelle Tabah-Fisch, Jim Cassidy	48
6	KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: The CRYSTAL experience 2008 ·Journal of Clinical Oncology ·Eric Van Cutsem, István Láng, G D’Haens, Vladimir Moiseyenko, J. Załuski, Gunnar Folprecht, Sabine Tejpar, O. Kisker, Christopher Stroh, P. Rougier	281
7	Primary resistance to docetaxel-based chemotherapy in metastatic breast cancer patients correlates with a high frequency of BRCA1 mutations 2008 ·Journal of Clinical Oncology ·Piotr J. Wysocki, Konstanty Korski, Katarzyna Lamperska, J. Załuski, Andrzej Maćkiewicz	6
8	Clinical data analysis using artificial neural networks (ANN) and principal component analysis (PCA) of patients with breast cancer after mastectomy 2007 ·Reports of Practical Oncology & Radiotherapy ·Adam Buciński, Tomasz Bączek, Jerzy Krysiński, (unknown), J. Załuski	21
9	Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen 2006 ·Annals of Oncology ·Miguel Martín, Aňa Lluch, Miguel Ángel Seguí, A. Ruíz, Manuel Ramos, Encarna Adrover, Álvaro Rodríguez-Lescure, Regina Große, Lourdes Calvo, Concepción Fernández‐Chacón, Montserrat Roset, A. Antón, Dolores Isla, Purificación Martínez del Prado, L. Iglesias, J. Załuski, Àngels Arcusa, José Manuel López-Vega, Montserrat Muñoz-Mateu, J. R. Mel	156
10	Randomized phase 3 trial of irinotecan (CPT-11) + 5FU/folinic acid (FA) vs CDDP + 5FU in 1^st-line advanced gastric cancer patients 2005 ·Journal of Clinical Oncology ·Magdolna Dank, J. Załuski, C. Barone, Vahur Valvere, C. Peschel, M. Wenczl, Erdem Göker, Marie‐Laure Risse, Lucile Awad, R. Bugat	73
11	Irinotecan in combination with 5-fluorouracil and folinic acid or with cisplatin in patients with advanced gastric or esophageal-gastric junction adenocarcinoma: results of a randomized phase II study 2004 ·Annals of Oncology ·Carmelo Pozzo, C. Barone, J. Szántó, (unknown), Christian Peschel, Johannes Bükki, В. А. Горбунова, Vahur Valvere, J. Załuski, M. Biakhov, Emmanuel Zuber, Christian Jacques, R. Bugat	126
12	Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial 2003 ·Annals of Oncology ·Werner Scheithauer, J McKendrick, S. Begbie, Markus Borner, W. Ivon Burns, Howard A. Burris, Jim Cassidy, Duncan I. Jodrell, P. Koralewski, E.L. Levine, Norbert Marschner, Jean A. Maroun, Pilar García‐Alfonso, Jerzy Tujakowski, Guy van Hazel, A. Wong, J. Załuski, Chris Twelves	222
13	1089 Improved safety of capecitabine vs bolus 5-FU/leucovorin (LV) as adjuvant therapy for colon cancer (the X-ACT phase III study) 2003 ·European Journal of Cancer Supplements ·(unknown), H. Kröning, Andrés Cervantes, (unknown), J. McKendrick, J. Schüller, C.J. Twelves, Alice Wong, J. Załuski, J.-Y. Douillard	3
14	Docetaxel and Doxorubicin Compared With Doxorubicin and Cyclophosphamide as First-Line Chemotherapy for Metastatic Breast Cancer: Results of a Randomized, Multicenter, Phase III Trial 2003 ·Journal of Clinical Oncology ·(unknown), Carla I. Falkson, Daniel de Castro, J. Szántó, Miguel Martín, Stephen Chan, Tadeusz Pieńkowski, J. Załuski, Tamás Pintér, Maciej Krzakowski, Daniel Vorobiof, Robert Leonard, Ian Kennedy, N. Azli, M Murawsky, A. Riva, P Pouillart	290
15	215 A randomized, multinational phase III study in first line metastatic and locally recurrent gastric cancer (MGC): CPT-11 plus 5-fluorouracil (5-FU)/leucovorin (LV) versus cisplatinum (CDDP) plus 5-FU 2003 ·European Journal of Cancer Supplements ·Magdolna Dank, J. Załuski, Carlo Barone, Vahur Valvere, (unknown), C. Peschel, Erdem Göker, M. Wenczl, Sylvie Assadourian, R. Bugat	4
16	Efficacy and safety of ITS fentanyl given directly after tramadol to patients withcancer related pain (based on FEN-POL-2 trial) 2002 ·Nowotwory Journal of Oncology ·J Łuczak, (unknown), Rodryg Ramlau, Marek Z. Wojtukiewicz, P. Koralewski, Maciej Krzakowski, J. Załuski	2
17	Rituximab (Mabthera<sup>TM</sup>, Rituxan<sup>TM</sup>) in Patients with Recurrent Indolent Lymphoma 2001 ·Medical Oncology ·Jan Walewski, Ewa Kraszewska, O Mioduszewska, Joanna Romejko‐Jarosińska, A. Hellmann, Jarosław Czyż, (unknown), (unknown), Sebastian Grosicki, Mieczysław Komarnicki, (unknown), Kazimierz Kuliczkowski, Tomasz Wróbel, Jadwiga Dwilewicz‐Trojaczek, Tadeusz Robak, Krzysztof Warzocha, J. Załuski, E. Wójcik, Anna Dmoszyńska, Adam Walter‐Croneck	17
18	Extraskeletal Ewing's sarcoma - a case report and review of the literature 2000 ·Nowotwory Journal of Oncology ·(unknown), (unknown), J. Załuski	6
19	Preliminary data of a phase II randomized trial of taxotere (TXT) and doxorubicin (DOX) given simultaneously or sequentially as 1st line chemotherapy (CT) for metastatic breast cancer (MBC) 1999 ·European Journal of Cancer ·И. А. Королева, Marek Z. Wojtukiewicz, J. Załuski, (unknown), M. Biakhov, (unknown), (unknown), (unknown), Clémence Dubois, (unknown)	5
20	Low weekly doses of doxorubicin and epidoxorubicin in second line chemotherapy of advanced breast cancer 1993 ·(unknown), Jacek Jassem, H Karnicka-Młodkowska, Jerzy Tujakowski, J. Załuski, (unknown), (unknown), E Solska	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact